Navigation Links
BioMS Medical announces receipt of milestone payment from Eli Lilly and Company
Date:9/22/2008

Canada and Europe and MAESTRO-03 in the United States. It additionally is being evaluated for relapsing remitting MS patients in a Phase II trial in Europe entitled MINDSET-01. In December 2007, BioMS entered into a licensing and development agreement granting Eli Lilly and Company exclusive worldwide rights to dirucotide (MBP8298) in exchange for an $87 million upfront payment, milestone payments and escalating royalties on sales. For further information please visit our website at http://www.biomsmedical.com.

This press release may contain forward-looking statements, which reflect the Company's current expectation regarding future events. These forward-looking statements involve risks and uncertainties that may cause actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Such factors include, but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process and other risks detailed from time to time in the Company's ongoing quarterly and annual reporting. Certain of the assumptions made in preparing forward-looking statements include but are not limited to the following: that MBP8298 will continue to demonstrate a satisfactory safety profile in ongoing and future clinical trials; and that BioMS Medical Corp. will complete the respective clinical trials within the timelines communicated in this release. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE BioMS Medical Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. BioMS Medical to present at Sachs Associates Biotech in Europe Forum
2. BioMS Medical to present at UBS Global Life Sciences Conference
3. BioMS Medicals lead drug, dirucotide (MBP8298) for the treatment of multiple sclerosis, receives fast track designation from FDA
4. BioMS Medical announces its intention to renew a normal course issuer bid
5. BioMS Medical announces positive interim analysis on phase III trial of dirucotide (MBP8298) for multiple sclerosis
6. BioMS Medical Announces Second Quarter 2008 Results
7. BioMS Medical completes patient recruitment in phase III U.S. multiple sclerosis trial
8. BioMS Medical to present at BMO Healthcare Conference
9. BioMS Medicals relapsing-remitting multiple sclerosis trial receives positive review from Data Safety Monitoring Board
10. BioMS Medical to present at Jefferies Healthcare Conference
11. BioMS Medical to present at 2008 BIO International Convention
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... September 02, 2014 Opertech Bio, ... highly efficient, cost effective approach to sensory evaluation, ... 8,820,265 by the U.S. Patent and Trademark Office, ... , “Opertech’s taste evaluation technology called ... automated high throughput system for rapid characterization of ...
(Date:9/2/2014)... 2, 2014 /PRNewswire/ - BIOREM Inc. (TSXV: BRM) ("Biorem" or "the ... orders consist of three large odour control systems for waste ... "These orders are consistent with the market resurgence in ... , President and CEO. "After a difficult period of restraint ... beginning to see sales growth. Our lower cost structure, technology ...
(Date:9/1/2014)... , Sept. 1, 2014 Reportlinker.com ... available in its catalogue: India Solid ... http://www.reportlinker.com/p02350445/India-Solid-Waste-Management-Vehicles-Market-Forecast-and-Opportunities-2019.html ... are the main governing bodies responsible for complete ... cities. On an average, around 135,000 MT solid ...
(Date:8/31/2014)... August 31, 2014 2014 ... is a professional and in-depth research report ... basic Polyacrylamide information, including Polyacrylamide definition, classification, ... as industry overview. This research covers the ... well as global industry analysis covering macroeconomic ...
Breaking Biology Technology:Opertech Bio Receives U.S. Patent for High-Throughput Taste Evaluation Technology 2India Solid Waste Management Vehicles Market Forecast and Opportunities, 2019 2India Solid Waste Management Vehicles Market Forecast and Opportunities, 2019 3India Solid Waste Management Vehicles Market Forecast and Opportunities, 2019 4India Solid Waste Management Vehicles Market Forecast and Opportunities, 2019 5India Solid Waste Management Vehicles Market Forecast and Opportunities, 2019 6India Solid Waste Management Vehicles Market Forecast and Opportunities, 2019 7India Solid Waste Management Vehicles Market Forecast and Opportunities, 2019 8International Polyacrylamide Industry & Copper Iodide Market Data Analysis Now Available at DeepResearchReports.com 2International Polyacrylamide Industry & Copper Iodide Market Data Analysis Now Available at DeepResearchReports.com 3
... Vanderbilt University have developed a new technique that uses a ... multiple points simultaneously, a method that could help scientists study ... shape. UV lasers are a commonly-used tool for ... vaporizing one point at a time in a series of ...
... 2011 GNS Healthcare, Inc. (GNS) announced today ... Brigham and Women,s Hospital (BWH) , a teaching affiliate of ... adverse drug events and on hospital readmissions for patients admitted ... excited to announce this collaboration with Dr. Bates, Brigham and ...
... Florida-based SkinHealth Technology introduces a powerful, breakthrough formula ... botanical emollients -- with a proven skin protectant to ... ExtremeSkinCare Intense Treatment Balm helps reduce ... relieve inflamed and irritated skin without steroids . ...
Cached Biology Technology:GNS Healthcare, Inc Collaborates with Nationally Ranked Hospital to Predict Adverse Drug Events and Hospital Readmissions 2GNS Healthcare, Inc Collaborates with Nationally Ranked Hospital to Predict Adverse Drug Events and Hospital Readmissions 3New Dermatological Formula Targets Psoriasis, Eczema and Other Extreme Skin Conditions 2
(Date:9/1/2014)... adapted to a life without light. They emit echolocation sounds ... distance to obstacles or prey. In their brains, they have ... out by researchers at Technische Universitt Mnchen (TUM) has shown ... external factors. , Closer objects appear larger ... an object, the number of activated neurons in its brain ...
(Date:8/31/2014)... have discovered that ,good, cholesterol is turned ,bad, by ... MG, was found to damage ,good, HDL cholesterol, which ... , Low levels of HDL, High Density Lipoprotein, ... of MG being common in the elderly and those ... funding from the British Heart Foundation (BHF) and published ...
(Date:8/31/2014)... the highly infectious bacteria C. diff , that ... by a team at the University of Leicester. , ... that it is possible to identify the unique ,smell, ... rapid diagnosis of the condition., What is more, the ... different strains of the disease simply from their smell ...
Breaking Biology News(10 mins):Zooming in for a safe flight 2Sugar substance 'kills' good HDL cholesterol, new research finds 2Scientists develop 'electronic nose' for rapid detection of C. diff infection 2
... National Center for Research Resources (NCRR), part of ... will provide up to an estimated $122 million ... Development Award (IDeA) Networks of Biomedical Research Excellence ... development, coordination and sharing of research resources and ...
... membership agreement with BioMed Central to cover publication costs ... BioMed Central membership arrangement means that Pfizer will centrally ... funded by Pfizer when they submit a research article ... journals. By funding open access publication fees in this ...
... water resources in river basins were acknowledged and managed ... researchers from Stockholm Resilience Centre at Stockholm University, Stockholm ... The challenge of meeting future water needs under ... demands for water may be less bleak than widely ...
Cached Biology News:NIH grants $122 million in Institutional Development Awards 2NIH grants $122 million in Institutional Development Awards 3Better water use could reduce future food crises 2Better water use could reduce future food crises 3
... The kit was tested on rat tissue extracts ... yeast ( S. cerevisae ) extract. It was ... tissues and cell lines. Application: A simple and ... fractions based on the detection of the inorganic ...
... CAST Equine EIA Principle: ... LTC4, LTD4 and LTE4 are ... by 5-lipoxygenase and glutathione-S-transferase. In ... termed "Slow Reacting Substances of ...
... stress is the condition in which a ... stimuli and the various antioxidants. Oxidative ... pathogenesis of several diseases, including artherosclerosis, chronic ... possesses several antioxidant systems that are very ...
... tested through 63 ligand ... spanning a broad therapeutic ... includes many non human ... non-selective assays. Used ...
Biology Products: